Abstract
Aim: Chylothorax is a rare but life-threatening condition in newborns. Octreotide, a somatostatin analogue, is widely used as a therapeutic option in neonates with congenital and acquired chylothorax, but its therapeutic role has not been clarified yet. Methods: We performed a systematic review to assess the efficacy and safety of octreotide in the treatment of congenital and acquired chylothorax in newborns. Comprehensive research, updated till 31 October 2017, was performed by searching in PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases using the MeSH terms ‘octreotide’ and ‘chylothorax’. Both term and preterm newborns with congenital or acquired chylothorax treated with octreotide within the 30th day of life were included. Octreotide treatment was considered effective if a progressive reduction/ceasing in drained chylous effusion occurred. Results: A total of 39 articles were included. Octreotide was effective in 47% of patients, with a slight but not significant difference between congenital (30/57; 53.3%) and acquired (9/27; 33.3%) chylothorax (P = 0.10). Marked variation in octreotide regimen was observed. The most common therapeutic scheme was intravenous infusion at a starting dose of 1 μg/kg/h, gradually increasing to 10 μg/kg/h according to the therapeutic response. Side effects were reported in 12 of 84 patients (14.3%). Only case reports were included in this review due to the lack of randomised controlled trials. Conclusion: Octreotide is a relatively effective and safe treatment option in neonates with chylothorax, especially for the congenital forms.
| Original language | English |
|---|---|
| Pages (from-to) | 840-847 |
| Number of pages | 8 |
| Journal | Journal of Paediatrics and Child Health |
| Volume | 54 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2018 |
Fingerprint
Keywords
- chylothorax
- infant
- newborn
- octreotide
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Octreotide for congenital and acquired chylothorax in newborns : A systematic review. / Bellini, Carlo; Cabano, Rita; De Angelis, Laura C.; Bellini, Tommaso; Calevo, Maria G.; Gandullia, Paolo; Ramenghi, Luca A.
In: Journal of Paediatrics and Child Health, Vol. 54, No. 8, 01.08.2018, p. 840-847.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Octreotide for congenital and acquired chylothorax in newborns
T2 - A systematic review
AU - Bellini, Carlo
AU - Cabano, Rita
AU - De Angelis, Laura C.
AU - Bellini, Tommaso
AU - Calevo, Maria G.
AU - Gandullia, Paolo
AU - Ramenghi, Luca A.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Aim: Chylothorax is a rare but life-threatening condition in newborns. Octreotide, a somatostatin analogue, is widely used as a therapeutic option in neonates with congenital and acquired chylothorax, but its therapeutic role has not been clarified yet. Methods: We performed a systematic review to assess the efficacy and safety of octreotide in the treatment of congenital and acquired chylothorax in newborns. Comprehensive research, updated till 31 October 2017, was performed by searching in PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases using the MeSH terms ‘octreotide’ and ‘chylothorax’. Both term and preterm newborns with congenital or acquired chylothorax treated with octreotide within the 30th day of life were included. Octreotide treatment was considered effective if a progressive reduction/ceasing in drained chylous effusion occurred. Results: A total of 39 articles were included. Octreotide was effective in 47% of patients, with a slight but not significant difference between congenital (30/57; 53.3%) and acquired (9/27; 33.3%) chylothorax (P = 0.10). Marked variation in octreotide regimen was observed. The most common therapeutic scheme was intravenous infusion at a starting dose of 1 μg/kg/h, gradually increasing to 10 μg/kg/h according to the therapeutic response. Side effects were reported in 12 of 84 patients (14.3%). Only case reports were included in this review due to the lack of randomised controlled trials. Conclusion: Octreotide is a relatively effective and safe treatment option in neonates with chylothorax, especially for the congenital forms.
AB - Aim: Chylothorax is a rare but life-threatening condition in newborns. Octreotide, a somatostatin analogue, is widely used as a therapeutic option in neonates with congenital and acquired chylothorax, but its therapeutic role has not been clarified yet. Methods: We performed a systematic review to assess the efficacy and safety of octreotide in the treatment of congenital and acquired chylothorax in newborns. Comprehensive research, updated till 31 October 2017, was performed by searching in PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases using the MeSH terms ‘octreotide’ and ‘chylothorax’. Both term and preterm newborns with congenital or acquired chylothorax treated with octreotide within the 30th day of life were included. Octreotide treatment was considered effective if a progressive reduction/ceasing in drained chylous effusion occurred. Results: A total of 39 articles were included. Octreotide was effective in 47% of patients, with a slight but not significant difference between congenital (30/57; 53.3%) and acquired (9/27; 33.3%) chylothorax (P = 0.10). Marked variation in octreotide regimen was observed. The most common therapeutic scheme was intravenous infusion at a starting dose of 1 μg/kg/h, gradually increasing to 10 μg/kg/h according to the therapeutic response. Side effects were reported in 12 of 84 patients (14.3%). Only case reports were included in this review due to the lack of randomised controlled trials. Conclusion: Octreotide is a relatively effective and safe treatment option in neonates with chylothorax, especially for the congenital forms.
KW - chylothorax
KW - infant
KW - newborn
KW - octreotide
UR - http://www.scopus.com/inward/record.url?scp=85044612508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044612508&partnerID=8YFLogxK
U2 - 10.1111/jpc.13889
DO - 10.1111/jpc.13889
M3 - Article
AN - SCOPUS:85044612508
VL - 54
SP - 840
EP - 847
JO - Journal of Paediatrics and Child Health
JF - Journal of Paediatrics and Child Health
SN - 1034-4810
IS - 8
ER -